Sol-Gel Technologies (SLGL) Enterprise Value (2018 - 2026)
Sol-Gel Technologies (SLGL) posted quarterly Enterprise Value of -$10.1 million for Q1 2026, up 39.99% year-over-year from -$7.2 million in Q1 2025, and up 57.76% quarter-over-quarter from -$24.0 million in Q4 2025.
Analysis
Sol-Gel Technologies (SLGL) Enterprise Value (2018 - 2026) Analysis & Trends
Sol-Gel Technologies (SLGL) has reported Enterprise Value for 11 consecutive years, with -$10.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value rose 39.99% year-over-year to -$10.1 million; the TTM figure through Mar 2026 stood at -$10.1 million (up 39.99% YoY), while the FY2025 annual figure was -$24.0 million, up 4.35% from the prior year.
- Enterprise Value improved to -$10.1 million in Q1 2026 per SLGL's latest filing, from -$24.0 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$6.7 million in Q3 2025 and bottomed at -$42.2 million in Q2 2022.
- Historically, Enterprise Value has averaged -$20.3 million across 5 years, with a median of -$21.1 million in 2022.
- On a YoY basis, Enterprise Value climbed as much as 80.39% in 2022 and fell as far as 68.07% in 2022.
- Sol-Gel Technologies' Enterprise Value stood at -$21.1 million in 2022, then slumped by 32.46% to -$28.0 million in 2023, then grew by 14.54% to -$23.9 million in 2024, then retreated by 0.36% to -$24.0 million in 2025, then surged by 57.76% to -$10.1 million in 2026.
- Business Quant data shows SLGL's Enterprise Value at -$10.1 million in Q1 2026, -$24.0 million in Q4 2025, and -$6.7 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Sol-Gel Technologies | 194.01 Mn | 146.08 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 158.64 Mn |
| Mar 31, 2026 | 167.89 Mn |
| Dec 31, 2025 | 93.41 Mn |
| Sep 30, 2025 | 74.49 Mn |
| Jun 30, 2025 | -62,360.93 |
| Mar 31, 2025 | -2.42 Mn |
| Dec 31, 2024 | 1.99 Mn |
| Sep 30, 2024 | -9.11 Mn |
| Jun 30, 2024 | -2.83 Mn |
| Mar 31, 2024 | 11.08 Mn |
| Dec 31, 2023 | 2.80 Mn |
| Sep 30, 2023 | 11.57 Mn |
| Jun 30, 2023 | 38.87 Mn |
| Mar 31, 2023 | 74.44 Mn |
| Dec 31, 2022 | 84.34 Mn |
| Sep 30, 2022 | 90.60 Mn |
| Jun 30, 2022 | 52.58 Mn |
| Mar 31, 2022 | 140.42 Mn |
| Dec 31, 2021 | 149.34 Mn |
| Sep 30, 2021 | 184.42 Mn |